Alembic Pharmaceuticals logo

Alembic Pharmaceuticals

APLLTD NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹16,055 Cr
Volatility
Moderate
P/E Ratio
23.11
EBITDA
₹1,173 Cr
Return on Equity
11.83%
Debt to Equity
0.25
Book Value
₹288.7
EPS
₹32.05
52W High
₹998
52W Low
₹635.8

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 35.7%

Weaknesses

5
  • Stock is trading at 2.82 times its book value
  • The company has delivered a poor sales growth of 6.37% over past five years.
  • Tax rate seems low
  • Company has a low return on equity of 12.7% over last 3 years.
  • Company might be capitalizing the interest cost

Growth Rate

Revenue Growth
10.2% higher than 3Y
Net Income Growth
15.26% lower than 3Y
Cash Flow Change
790% higher than 3Y
ROE
5.44% lower than 3Y
ROCE
-12.89% lower than 3Y
EBITDA Margin (Avg.)
1.28% lower than 3Y

AI Analysis — Bull vs Bear

5d ago
AI opinion · based on fundamentals
Risk medium

Alembic Pharmaceuticals has a market capitalisation of about ₹16,557 crore. It trades at a P/E of 24.2x and a P/B of 2.94x, with a dividend yield of 1.41%. Profit has grown 26% TTM and at a 28% 3-year CAGR, but 5-year profit CAGR is -9% and 10-year is 0%. Sales have compounded at 6% over 5 years, ROE has averaged 13% over 3 years, and the stock has returned 2% CAGR over 5 years and -5% over the past year.

Bull Case 7
  • Profit has compounded at 28% over the past 3 years, a sharp recovery from the earnings trough reflected in the -9% 5-year profit CAGR.
  • TTM profit growth of 26% is running well ahead of TTM sales growth of 14%, which points to operating leverage and possibly better margins.
  • TTM sales growth of 14% is faster than the 3-year (9%) and 5-year (6%) sales CAGRs, so the top line appears to be speeding up.
  • The company pays out about 35.7% of profits as dividends, for a dividend yield of 1.41%, giving shareholders some cash return.
  • ROE has held at 13% for both the last year and the 3-year average, up from the 5-year average of 11%, so returns have stabilised and improved.
  • 10-year sales CAGR of 9% shows the business has grown its revenue over a long period, with a record stretching across more than one cycle.
  • Weak stock returns (2% 5-year CAGR, 3% 10-year CAGR) while profits recovered at 28% over 3 years mean less of the earnings recovery is already reflected in the price than would otherwise be the case.
Bear Case 7
  • 5-year profit CAGR is -9% and 10-year profit CAGR is 0%, so long-term earnings are flat to lower despite the recent rebound.
  • 5-year sales growth of 6.37% is modest for a pharma company and trails the 9% 10-year sales CAGR, showing a slowdown in the medium term.
  • 3-year average ROE of 12.7% and 10-year ROE of 16% show capital efficiency has fallen from its historical levels.
  • Shareholder returns have been weak: 5-year stock CAGR of 2%, 10-year of 3%, and -5% over the past year.
  • At a P/E of 24.2x and P/B of about 2.94–2.99x with ROE near 13%, the valuation depends on the recent profit growth continuing.
  • The company may be capitalising interest cost, which can flatter reported profit. Some of the 26% TTM profit growth could come from accounting treatment rather than operations.
  • The tax rate looks low. If it normalises, the 26% TTM profit growth could be harder to sustain.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

21h ago
Neutral 1
  • Investor meetings in Mumbai Sep 18

    Alembic Pharmaceuticals will hold one-to-one meetings with institutional investors and analysts in Mumbai on September 23, 2026. The company said discussions will be based only on publicly available information, so no new material disclosures are expected.

TL;DR: The news flow for Alembic Pharmaceuticals is thin, with only one routine item: institutional investor meetings scheduled for September 23, 2026. Meetings like this are standard investor-relations activity and do not change the fundamentals or signal new risks. With no earnings, regulatory, or product news in this set, the trend can't be judged from these articles alone. Investors should watch for USFDA inspection outcomes, US generics launches, and the next quarterly results for clearer direction.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1,486
1,595
1,631
1,517
1,562
1,648
1,693
1,770
1,711
1,910
1,876
1,848
2,150
Expenses
1,287
1,387
1,364
1,257
1,325
1,409
1,433
1,498
1,430
1,594
1,585
1,620
1,818
Operating Profit
199
208
266
260
237
239
260
271
281
316
292
228
332
OPM %
13%
13%
16%
17%
15%
15%
15%
15%
16%
17%
16%
12%
15%
Other Income
12
10
3
4
2
30
10
14
6
8
-27
2
15
Interest
14
16
15
11
13
19
22
25
24
24
23
23
28
Depreciation
66
68
69
69
69
71
70
69
74
76
80
89
98
PBT
130
135
185
183
157
180
178
192
190
224
162
119
222
Tax %
7%
-1%
2%
3%
14%
15%
23%
18%
19%
18%
18%
-70%
22%
Net Profit
121
137
180
178
135
153
138
157
154
184
132
202
172
EPS in Rs
6.14
6.95
9.18
9.07
6.85
7.8
7.04
7.98
7.85
9.4
6.76
10.31
8.8
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
2,056
3,166
3,105
3,131
3,935
4,606
5,393
5,306
5,653
6,229
6,672
7,345
7,784
Expenses
1,653
2,159
2,490
2,488
3,061
3,383
3,913
4,432
4,970
5,296
5,664
6,224
6,617
Operating Profit
403
1,007
615
643
874
1,223
1,480
874
682
932
1,008
1,121
1,167
OPM %
20%
32%
20%
21%
22%
27%
27%
16%
12%
15%
15%
15%
15%
Other Income
4
7
2
7
9
-39
87
56
-2
28
56
-14
-1
Interest
4
5
5
3
18
27
16
18
50
56
79
94
98
Depreciation
44
72
83
105
115
157
183
287
275
273
279
319
342
PBT
359
936
529
541
749
1,000
1,368
625
355
632
707
694
726
Tax %
21%
23%
23%
22%
21%
20%
19%
17%
4%
3%
18%
3%
—
Net Profit
283
720
403
413
583
801
1,146
521
342
616
582
671
690
EPS in Rs
15.01
38.2
21.39
21.89
31
43.97
58.33
26.5
17.4
31.33
29.68
34.33
35.27
Div. Payout %
23%
9%
19%
18%
18%
23%
24%
38%
46%
35%
37%
35%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
38
38
38
38
38
38
39
39
39
39
39
39
Reserves
847
1,560
1,865
2,182
2,681
3,182
5,028
5,198
4,331
4,779
5,152
5,636
Borrowings
264
114
89
708
1,128
1,747
584
717
722
513
1,258
1,430
Other Liabilities
493
718
698
1,013
931
1,022
1,058
1,167
1,090
1,114
1,325
1,658
Total Liabilities
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
7,773
8,763
Fixed Assets
547
708
799
993
1,158
1,552
1,788
1,798
2,398
2,547
2,524
3,081
CWIP
83
93
396
1,010
1,551
1,846
2,183
2,304
601
524
837
683
Investments
2
87
50
42
49
18
236
118
96
93
127
141
Other Assets
1,009
1,541
1,444
1,896
2,019
2,573
2,502
2,902
3,087
3,281
4,285
4,858
Total Assets
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
7,773
8,763
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
172
948
329
312
812
449
1,463
552
724
803
88
783
Investing
-256
-307
-486
-884
-756
-731
-840
-372
-448
-321
-568
-506
Financing
87
-224
-129
503
59
155
-597
-217
-262
-438
444
-164
Net Cash Flow
3
417
-286
-69
115
-127
26
-37
14
45
-37
113
Free Cash Flow
-52
647
348
-495
49
-285
804
128
282
487
-466
290
CFO/OP
60
114
73
70
112
56
115
77
115
88
16
79
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
64
40
40
61
45
69
24
56
68
60
77
73
Inventory Days
196
266
269
302
356
417
431
406
315
350
466
462
Days Payable
166
264
213
313
237
220
194
178
145
157
179
154
Cash Conversion Cycle
94
42
96
51
164
266
261
283
237
253
363
381
Working Capital Days
32
36
61
69
24
50
73
74
77
88
87
87
ROCE %
38%
66%
29%
22%
23%
24%
26%
11%
7%
13%
13%
13%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Alembic Pharmaceuticals insights

68 extracted metrics + investor summaries across FY11–FY27.

Log in — free

Shareholding Pattern

Others3.03%Promot.69.87%FIIs4.18%Public6.97%DIIs15.94%As ofJun 2026

Documents

Frequently Asked Questions about Alembic Pharmaceuticals

What does Alembic Pharmaceuticals Ltd do?
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities.
Where is Alembic Pharmaceuticals Ltd (APLLTD) listed?
Alembic Pharmaceuticals Ltd trades as APLLTD on the NSE and under code 533573 on the BSE.
Which sector does Alembic Pharmaceuticals Ltd belong to?
Alembic Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd has a market capitalisation of ₹16,055 Cr, which places it in the Mid Cap band.
What is the PE ratio of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd trades at a PE ratio of 23.11, on earnings per share of ₹32.05, against a book value of ₹288.7 per share.
What is the 52-week high and low of Alembic Pharmaceuticals Ltd?
Over the last 52 weeks Alembic Pharmaceuticals Ltd has traded between ₹635.8 and ₹998.
Does Alembic Pharmaceuticals Ltd pay dividends?
Alembic Pharmaceuticals Ltd has a dividend yield of 1.45%.
What is the Return on Equity (ROE) of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd reported a return on equity of 11.83%. Its debt-to-equity ratio is 0.25.

Company Information

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities.

Website alembic-india.com
CEO Mr. Chirayu Ramanbhai Amin
Employees 16,571
Listed 2011-09-20
Face Value ₹ 2
Issued Size 19,65,63,124

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/APLLTD.md for Alembic Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List